Statistics for Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.
Total visits
views | |
---|---|
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. | 14 |
Total visits per month
views | |
---|---|
January 2024 | 0 |
February 2024 | 0 |
March 2024 | 0 |
April 2024 | 0 |
May 2024 | 0 |
June 2024 | 0 |
July 2024 | 0 |
Top country views
views | |
---|---|
United States | 9 |
China | 3 |
Thailand | 2 |
Top city views
views | |
---|---|
Roanoke | 5 |
Spring Hope | 3 |
Phitsanulok | 2 |
Chaohu | 1 |
Hangzhou | 1 |
Hongkou | 1 |